Genetic mutation detection kit YZYMT-003

for lung cancercolorectal cancerfor BRAF mutations

Human BRAE Gene Mutations Detection Kit (PCR-Fluorescence Probe Method) This product is used to qualitatively detect the V600E mutation of BRAF gene in the DNA extract of paraffin-embedded pathological tissue samples of colorectal cancer in vitro. BRAF gene, the full name of which is v-Raf murine sarcomaviral oncogene homolog B1, was discovered and cloned by IKawa and others in 1988 during the process of inducing the proliferation of primary avian cells and the transformation of NIH3T3 cells. It belongs to the RAF gene family with ARAF and CRAF, and is located on human chromosome 7q34, with a size of about 190 kb. Its functional coding region is composed of 2510 base pairs, It encodes serine threonine protein kinase in MAPK pathway, which transduces signals from RAS to MEK1/2, and thus participates in regulating various biological events in cells. BRAF mutations occur in nearly 8% of human tumors, mainly in colorectal cancer, melanoma and thyroid papillary carcinoma. According to statistics, about 15% of colon cancer patients have somatic BRAF gene mutations. 11% of the mutations were located in the glycine ring of exon 11; 89% of mutations occurred in the active region of exon 15, of which about 92% were located in the 1799 nucleotide (T mutation was A), resulting in the substitution of its encoded valine by glutamic acid (V600E). Some studies have pointed out that targeted treatment with anti-EGFR antibody is ineffective for colorectal cancer patients with KRAS wild-type but BRAF V600E mutation. The NCCN Clinical Practice Guide for Colorectal Cancer in 2011 recommended that the BRAF genotype should be further detected in patients with KRAS wild type.